RT Journal Article
SR Electronic
T1 2022-RA-934-ESGO Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity sub-study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A34
OP A35
DO 10.1136/ijgc-2022-ESGO.74
VO 32
IS Suppl 2
A1 Isabelle Suvaal
A1 Kathrin Kirchheiner
A1 Remi Nout
A1 Alina Sturdza
A1 Erik van Limbergen
A1 Jacob Lindegaard
A1 Hein Putter
A1 Ina Jürgenliemk-Schulz
A1 Cyrus Chargari
A1 Kari Tanderup
A1 Richard Pötter
A1 Carien Creutzberg
A1 Moniek ter Kuile
YR 2022
UL http://ijgc.bmj.com/content/32/Suppl_2/A34.3.abstract
AB Introduction/Background The EMBRACE Vaginal Morbidity sub-study prospectively evaluated physician-assessed vaginal changes and patient-reported-outcomes (PRO) on vaginal and sexual functioning problems, and sexual distress in the first 2 years after radio(chemo)therapy with image-guided adaptive brachytherapy for locally advanced cervical cancer.Methodology Eligible patients had FIGO 2009 stage IB2-IIIB cervical cancer with no or only limited (≤5 mm) vaginal involvement. Comprehensive assessment of vaginal changes was done before treatment, at 4–6 weeks and 3, 6, 12 and 24 months thereafter using CTCAE v3.0 and additional assessments. PRO were assessed at the same timepoints using validated Quality of Life (EORTC QLQ-C30 and CX24) and sexual questionnaires. Statistical methods included generalized linear mixed model analysis and Spearman’s rho correlation coefficients.Abstract 2022-RA-934-ESGO Figure 1 Vaginal changes clinical measuremnts over time (some of the CTCAE and additional assessments). The proportion of woman is shown in percentages. BM = baseline measurement; CTCAE = common terminology criteria for adverse events; DM = diameter; M = months; N = number of woman astrisk at the specific timepoint; O = observed number of women at the specific timepoint; W = weeksResults 113 eligible patients were included. Over time, mild (grade 1) vaginal changes were reported in 10.8–36.8% of the participants. Of the 113 participants, 46.7% reported not being sexually active at 24 months, mostly because of losing interest in sex or lacking a partner. Among the sexually active women (41–54/113), 43.2–51.3% reported vaginal functioning problems starting at 4–6 weeks and more severe sexual problems and distress were reported by 5–15% of them. Significant differences (p≤.05) in physician-assessed vaginal morbidity were found between baseline and follow-up, without further clear changes. No or only small associations between vaginal changes and vaginal functioning problems and sexual distress were found.Conclusion Relatively mild vaginal changes were reported after image-guided radio(chemo)therapy and brachytherapy according to EMBRACE-protocol. Vaginal functioning problems were reported by almost half of the sexually active women, while more severe problems and distress were reported by up to 15% of them. These results are favourable compared to previous data, potentially due to the combination of tumours with limited vaginal involvement and EMBRACE-specific treatment optimization and rehabilitation recommendations.